NCT04260022 2025-11-05Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLAscentage Pharma Group Inc.Phase 1 Recruiting242 enrolled
NCT01667133 2022-06-13A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)TakedaPhase 1/2 Completed35 enrolled 36 charts
NCT00967343 2021-06-14Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical DonorKiadis PharmaPhase 2/3 Terminated40 enrolled 10 charts
NCT03638206 2019-12-11Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesShenzhen BinDeBio Ltd.Phase 1/2 Unknown73 enrolled
NCT00464113 2015-08-21Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic LeukemiaExelixisPhase 1 Terminated49 enrolled
NCT00100152 2015-05-27A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)Merck Sharp & Dohme LLCPhase 1 Terminated50 enrolled
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts